On Thursday Wockhardt announced that the Drug Controller General of India (DCGI) has approved two of its new antibiotics, EMROK (IV) and EMROK-O for acute bacterial skin and skin structure infections, including diabetic foot infections and concurrent bacteraemia, thereby, becoming the first Indian company to achieve approval for newly-discovered antibiotics.